Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval

NCT06441214 is registered in ClinicalTrials.gov with Fondazione Italiana Linfomi - ETS as lead sponsor.

NCT NCT06441214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06441214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval
Lead sponsor
Fondazione Italiana Linfomi - ETS
Phase
Observational
Overall status
Active, not recruiting
Start date
December 13, 2024
Completion date
December 31, 2026
Enrollment
212 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

waldenström's macroglobulinemia (wm)